Drive, Farmington, CT, 06032, USA. abnormalities before and after disease recurrence. We outline an effort 1 4 4
to systemically catalogue the longitudinal changes in gliomas, the 1 4 5
Glioma Longitudinal Analysis Consortium. The GLASS initiative will 1 4 6 provide essential insights into the evolution of glioma towards a lethal 1 4 7 phenotype with the potential to reveal targetable vulnerabilities, and 1 4 8 ultimately, improved outcomes for a patient population in need. on the basis of glioma-intrinsic genes has maintained the proneural, classical, and 3 9 9 mesenchymal classes 63 . Determining subtypes in a cohort of 91 IDH-wildtype GBM 4 0 0 showed subtype switching following therapy and disease relapse in 45% of the 4 0 1 cohort 63 . These patterns converged with changes in the tumor microenvironment, Nearly all IDH-mutant gliomas exhibit a characteristic CpG island The major obstacle to glioma patients currently is a lack of effective treatments, yet how treatment affects glioma progression, a needed step towards integration of they are currently outside the scope of GLASS, but may be considered in the future 5 7 9
as the project evolves or as part of specific subprojects. Similarly subsets of the 5 8 0 GLASS cohort will be compared longitudinally by spatial correlation using multisector heterogeneity. Where available, these will be correlated with conventional and novel 5 8 4
MR imaging to explore spatiotemporal heterogeneity noninvasively. We aim to take (including under pressure of standard therapy).
8 8
Comprehensive genomic sequencing is needed to identify patterns of disease 5 8 9 evolution as well as key mutations and chromosomal alterations that confer 5 9 0 resistance to standard radiation, temozolomide, and novel clinical trial therapies.
9 1
Sequencing paradigms and their costs are rapidly evolving, and each method 5 9 2
provides different but often complementary information. There is no consensus on 5 9 3 optimal methods. With the accessibility of $1000 per biospecimen whole genome regions, but does not interrogate noncoding regions of the genome, structural variants, or noncoding copy number variants. The comprehensive nature of WGS 5 9 8 enables analysis of evolution and clonality at higher resolution. WGS and WES 5 9 9
combined may provide the optimal window on the breadth, depth, and allelic fraction 6 0 0 of somatic events. However, where limitations in tissue or resources mandate a 6 0 1 choice of one or the other, the decision will depend on the purpose of the (sub) The area of viable tumor tissue should be at least 50 mm 2 and the tumor cell 6 1 5
percentage should be higher than 50%. Hematoxylin and eosin slides of each 6 1 6 sample will be digitized by an automated slide scanner and the images will be stored recurrent tumor has to be submitted for review to the committee with information on genotype with clinical and morphological phenotype remains to be fully exploited in mechanisms of response and resistance and exposed therapeutic vulnerabilities will 6 3 6 be fed into current and future clinical trial designs by GLASS investigators and trials 6 3 7 designed collaboratively in academia and industry or across both. This strategy will 6 3 8
require an integrated bioinformatics interface across the molecular and clinical research. The necessary data processing infrastructure will be developed by the processing, data management and data sharing. A characteristic of the GLASS 6 5 0 consortium is that data will be generated at multiple institutions distributed over 6 5 1 multiple countries. As the regulations pertaining to ethical use of sequencing 6 5 2 datasets are continuously evolving, GLASS will follow the example set by ICGC to sensitive raw sequencing data. The GLASS data infrastructure committee has 6 5 5
developed Docker software images that can be shared by participating institutions to or more software tools to establish a workflow resembling an executable application.
6 5 8
Comparable to platform-independent Java software, the ready-to-run Docker images The data infrastructure committee will also coordinate mechanisms for 6 6 8
dissemination of results, as to widely share datasets with the community. We may 6 6 9 explore mechanisms such as the Genomic Data Commons, or similar, in order to 6 7 0 align our efforts with other molecular profiling studies. have given written informed consent. Data will be made available rapidly after 6 7 9 generation for community research use. Publication guidelines will follow that 6 8 0 established by the TCGA policy for authorship and publication. into mechanisms used by gliomas to defy therapeutic challenges. For example, 6 9 4
hypermutation following temozolomide treatment occurs in up to 15% of glioma, but 6 9 5 too few samples have been profiled to understand what is driving this process or to 6 9 6
identify biomarkers predictive of a TMZ associated hypermutator phenotype. GLASS 6 9 7
will have the power to identify molecular markers indicating evolution from newly 6 9 8
diagnosed to highly aggressive therapy-resistant malignancy, in addition to 6 9 9 molecular aberrations that occur under pressure from different therapeutic 7 0 0
modalities. It will also allow for the identification of currently undiscovered molecular 7 0 1 targets for resistance-prevention agents that might be co-administered with classical clinical trials and develop therapies that will extend survival and improve the quality to offer datasets of longitudinally profiled glioma patients or the availability of suitable 7 1 2 tissue samples.
In summary, we hope that through the GLASS Consortium, we continue the The GLASS Consortium is indebted to the support from the National Brain Tumor 
